Klow80
Four peptides, four repair axes documented separately. Klow80 raises the same question as any research complex: what do we really know about the whole, rather than each part?
- Research Use Only
- Molecule under study
- Living document
View the corresponding reference in the shop
- Current research state
- An experimental complex combining four peptides individually studied in preclinical research.
- Current clinical phase
- No clinical trial dedicated to the combination — available data concern each peptide separately.
- Last update
- 21 July 2026 · Reference fact sheet v1.0
- Living document
- Updated regularly as research progresses.
What is Klow80?
Klow80 is a research complex combining four distinct peptides in a single lyophilized vial.
The formulation adds a fourth peptide, KPV, to the Glow70 trio (GHK-Cu, BPC-157, TB-500). This tripeptide, derived from α-MSH, is studied for its potential involvement in research on inflammatory responses.
Like any multi-peptide complex, Klow80 is presented for educational and reference purposes — no clinical trial has validated the combination in humans.
Names you may come across
This molecule may appear under several names in the scientific, clinical or technical literature. Here are the main designations you may come across.
Name of the PHL complex, total content 80 mg.
Technical description of the formulation.
Common functional description.
Understanding it simply
Three simple reference points for understanding Klow80.
Four peptides, four areas
GHK-Cu (skin matrix), KPV (inflammatory responses), BPC-157 (repair), TB-500 (cell migration, data mainly from full-length thymosin β4) — each studied separately.
The specific contribution of KPV
KPV is a tripeptide (Lys-Pro-Val) derived from the C-terminal portion of α-MSH. It is studied in research on cutaneous and gastrointestinal inflammatory responses.
A complex, not a medicine
Klow80 remains a research protocol. No clinical evidence validates this exact combination in humans.
What research shows today
Science advances step by step. We clearly distinguish what is firmly established from what remains under study.
- GHK-Cu: extensively documented in vitro effects and topical cosmetic effects. — established
- KPV: a C-terminal tripeptide of α-MSH, studied preclinically in research on inflammatory responses. — established
- BPC-157: numerous preclinical studies on tissue repair. — established
- TB-500: cell migration and angiogenesis data come mainly from full-length thymosin β4; studies specific to the fragment are limited. — established
- Human data for the fixed combination of the four peptides: absent. — ongoing
Each constituent peptide is individually documented; the four-component complex has not undergone dedicated clinical trials.
What the research shows
- GHK-Cu: documented in vitro effects on the extracellular matrix and topical cosmetic use.
- KPV: preclinical and in vitro studies within research on cutaneous and gastrointestinal inflammation.
- BPC-157: wound-healing-promoting effects described in numerous preclinical models.
- Full-length thymosin β4: cell migration and angiogenesis described preclinically; limited data for the TB-500 fragment.
What still remains to be studied
- Pharmacokinetic behavior of the mixture in humans — not characterized.
- Potential synergies or interactions between the four peptides — not studied clinically.
- Long-term tolerability of the fixed combination — unknown.
What we know today
Not all information carries the same weight of evidence. We therefore present it across three clearly distinct levels, from the most solid to the most indicative.
What scientific publications show
Scientific evidence- Scientific publications address each peptide separately; no significant publication examines the exact combination of all four.
- Studies on KPV explore, in particular, its relevance to research on inflammatory gastrointestinal and skin diseases.
What some professionals report
Documented- Clinician authors emphasize that the evidence for each component does not automatically apply to a fixed combination.
- There are no official clinical recommendations for this type of complex.
What the community reports
Field observations- Community reports concern experimental uses, without standardization or objective data.
- Individual observations do not replace clinical trials.
The level of evidence for the Klow80 complex is uneven: strong for each individual peptide, very limited for the combination.
How does Klow80 work?
Klow80 explores four distinct biological pathways through its four components.
- Skin fibroblasts (GHK-Cu)
- Possible effects on the production of collagen, elastin and other tissue-supporting materials.
- Inflammatory pathways (KPV)
- Modulation of pro-inflammatory mediators studied in several preclinical models.
- Repair pathways (BPC-157)
- Effects on growth factors and wound healing studied in several preclinical models.
- Actin cytoskeleton (thymosin β4)
- Actin binding and the effect on cell migration are described for full-length thymosin β4; whether the TB-500 fragment retains them is poorly documented.
These mechanisms are described for each peptide individually. Combining them in a single vial does not mean that additive effects have been demonstrated.
Clinical trials timeline
A molecule under study progresses step by step. Here, simply, is where the research currently stands.
- Research· 1970s-1980sCompleted
Isolation of GHK and characterization of its copper complex
The scientific foundations for the GHK-Cu component are established.
- Research· 1990sCompleted
Preclinical studies of KPV
Work on the C-terminal fragment of α-MSH and inflammation-related research.
- Research· 1990s-2000sCompleted
Preclinical studies of BPC-157
Numerous published animal models of tissue repair.
- Research· 2000sCompleted
Characterization of thymosin β4
Preclinical studies on full-length thymosin β4 (cell migration, angiogenesis); the TB-500 fragment has been studied far less.
- Formulation· CurrentlyOngoing
Multi-peptide complexes in research
Emergence of fixed combinations to explore complementary mechanisms — not clinically validated.
Available analyses
Analytical documents provided by suppliers and published for Klow80, available in the Analysis Library. They document batch traceability and are not an independent analysis performed by PHL.
Open the analysis libraryFrequently asked questions
Is Klow80 a medicine?
No. It is a research complex (Research Use Only). No therapeutic use is suggested.
How does it differ from Glow70?
Klow80 adds the peptide KPV (10 mg), which is studied in research on inflammatory responses — Glow70 does not contain it.
What do we know about KPV?
Established: KPV is the C-terminal tripeptide of α-MSH (Lys-Pro-Val). It is studied preclinically and in vitro in research on cutaneous and gastrointestinal inflammation.
Are there any clinical trials on Klow80?
No. To our knowledge, there is no clinical trial dedicated to this specific combination in humans.
Do the data for individual peptides apply to Klow80?
In part. They concern each peptide in isolation — combining them in a single vial creates a biological context that has not been studied clinically.
Scientific publications
Reference bibliography covering each individual peptide — no publication specifically addresses the Klow80 complex.
α-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs
Luger T. A., Brzoska T. · Annals of the Rheumatic Diseases · 2007
Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract
Sikiric P. et al. · Current Pharmaceutical Design · 2013
Thymosin β4: actin-sequestering protein moonlights to repair injured tissues
Goldstein A. L., Hannappel E., Kleinman H. K. · Trends in Molecular Medicine · 2005
Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease
Kannengiesser K. et al. · Inflammatory Bowel Diseases · 2008
Glossary
- α-MSH
- Melanocyte-stimulating hormone; its C-terminal fragment (KPV) is studied for its own properties.
- Tripeptide
- A chain of three amino acids, the building blocks of proteins.
- Complex
- Combination of several molecules in a single formulation.
- Fibroblast
- A connective-tissue cell that makes collagen and other material supporting nearby cells.
- Angiogenesis
- Formation of new blood vessels from existing vessels.
Continue your discovery
Read next
Sheets that are thematically close. These links serve reading and discovery — they suggest no combined use.
Reference fact sheet — version 1.0, updated on 21 July 2026. The full regulatory and scientific framework is gathered in the “Important information” box at the top of the fact sheet.
Explore the fundamentals related to this goal
This general content is independent of the molecule and is neither a use strategy nor a protocol.